Incidence of Kidney Disease

Benzinga  Sep 29  Comment 
Brean Capital assumes coverage of Akebia Therapeutics Inc (NASDAQ: AKBA) with a Buy rating, with a lowered target price of $18, citing potential success of its anemia drug. The company's lead product candidate, AKB-6548 or vadadustat is a small...
MedPage Today  Sep 28  Comment 
(MedPage Today) -- Korean study suggests some shift in risks for kidney disease patients
The Hindu Business Line  Sep 19  Comment 
Dr Reddy’s Laboratories Ltd (DRL) has launched paricalcitol injection, a therapeutic equivalent generic version of Zemplar (paricalcitol) injection, in the US market. The vaccination is used in treat...
FiercePharma  Sep 13  Comment 
Not to be left behind in the SGLT2 race, AZ launches heart, kidney failure outcomes studies for Farxiga chelfand Tue, 09/13/2016 - 11:40
Benzinga  Sep 11  Comment 
Make sure you have a pot of coffee ready. Martin Shkreli will join PreMarket Prep for an exclusive interview on Monday at 8:15 a.m. ET. Last week, Retrophin Inc (NASDAQ: RTRX) announced positive results from sparsentan, a mid-stage clinical...
Benzinga  Sep 8  Comment 
JMP has reiterated its Market Outperform rating on Retrophin Inc (NASDAQ: RTRX). The recently held expert call suggests recent DUET data for sparsentan are impressive, but JMP would like over a year's worth of data in order to see the full impact...
Benzinga  Sep 7  Comment 
After his former company Retrophin Inc (NASDAQ: RTRX) released positive top-line data from the Phase 2 DUET study of sparsentan, Martin Shkreli offered an olive branch to media companies wishing to speak to him on the drug he helped...
Benzinga  Sep 7  Comment 
Martin Shkreli, the so-called "most hated man on the Internet" is making news again. Retrophin Inc (NASDAQ: RTRX), a bio-pharmaceutical company that focuses on therapies for the treatment of rare diseases, saw its shares surge Wednesday. The...
MedPage Today  Aug 10  Comment 
(MedPage Today) -- GFR impairment rises but albuminuria falls

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki